1. Pink Sheet

FDA Referees Tablet Scoring Skirmish: Brand And Generic May Have Different Lines

 
• By Brenda Sandburg

FDA denied Warner Chilcott’s citizen petition requesting the agency not approve ANDAs referencing Doryx unless they were for dual-scored tablets; Mylan must make change from single-score in its second manufacturing run.

FDA thoroughly rejected Warner Chilcott’s attempt to block approval of a generic version of its antibiotic Doryx (doxycycline) on the grounds the generic tablet is not dual scored. The agency asserted that there is little chance that marketing a single-scored tablet concurrently with a dual-scored tablet for a limited period of time would lead to a safety issue.

Warner Chilcott filed a citizen petition on Sept. 23 asking the agency not to approve any doxycycline 150 mg dose...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Animal Testing: US And EU Regulatory Support Grows For Alternatives, But Validation A Hurdle

 
• By Eliza Slawther

In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.

Senate Panel Approves US CDC Director Candidate Monarez With Measles Outbreak Growing

 
• By Cathy Kelly

The Senate Health, Education, Labor and Pensions Committee voted to advance Monarez's nomination to lead the CDC as the agency announced the largest US measles outbreak in 22 years.

US FDA Advisory Committee Supports Vaccine Safety, Scrutinizes AE Reporting Quality

 
• By Sue Sutter

The Pediatric Advisory Committee supported routine safety monitoring for three vaccines and 21 drugs, but the panel’s consumer representative said adverse event reporting needs improvement and FDA literature reviews should include lawsuits as well as social media.